Congenital Myelodysplastic Syndrome in a Newborn With Germline JAK2 Variant Treated With Liposomal Cytarabine-Daunorubicin and Allogeneic Hematopoietic Stem Cell Transplant.
0/5 보강
APA
Zorn KE, Bone KM, et al. (2026). Congenital Myelodysplastic Syndrome in a Newborn With Germline JAK2 Variant Treated With Liposomal Cytarabine-Daunorubicin and Allogeneic Hematopoietic Stem Cell Transplant.. Pediatric blood & cancer, 73(2), e70053. https://doi.org/10.1002/1545-5017.70053
MLA
Zorn KE, et al.. "Congenital Myelodysplastic Syndrome in a Newborn With Germline JAK2 Variant Treated With Liposomal Cytarabine-Daunorubicin and Allogeneic Hematopoietic Stem Cell Transplant.." Pediatric blood & cancer, vol. 73, no. 2, 2026, pp. e70053.
PMID
41454825 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Reawakening Differentiation Therapy in Acute Myeloid Leukemia: A Comprehensive Review of ATRA-Based Combination Strategies.
- Beyond initial response: Acquired resistance to hypomethylating agents in myeloid malignancies.
- Clinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry.
- Preclinical evaluation of CPL423: a novel potent small-molecule inhibitor of TAM family and FLT3 kinase for cancer therapy.
- Allicin inhibits PD-L1 through the IL-6/JAK2/STAT3 pathway to suppress immune evasion in osteosarcoma.
- Breviscapine inhibits the proliferation and immune escape of diffuse large B-cell lymphoma cells by regulating JAK2/STAT3/PD-L1 pathway.